1. CPMP: Note for guidance on the investigation of bioavailability and bioequivalence. Technical Report, Committee for Proprietary Medicinal Products, European Medicines Agency (2001)
2. CHMP: Guideline on the investigation of bioequivalence. Technical Report, Committee for Medicinal Products for Human Use, European Medicines Agency (2010)
3. Tothfalusi, L., Endrenyi, L., Midha, K.: Scaling or wider bioequivalence limits for highly variable drugs and for the special case of C(max). Int. J. Clin. Pharmacol. Ther. 41(5), 217–225 (2003)
4. Karalis, V., Symillides, M., Macheras, P.: Novel scaled average bioequivalence limits based on GMR and variability considerations. Pharm. Res. 21(10), 1933–1942 (2004)
5. CDER: Bioavailability and bioequivalence studies for orally administered drug products: general considerations. Technical Report, Center for Drug Evaluation and Research, Food and Drug Administration (2003)